Search research articles
Contact Us
Filters
Showing results (21-30 of 31) with videos related to
Page
of 4
Sort By:
Revista Espanola De Medicina Nuclear
|
June 10, 2006
[Striatal dopamine transporter density decrease in first episode schizophrenic patients treated with risperidone]
J J Mateos, F Lomeña, E Parellada, et al.
Journal of Psychopharmacology (Oxford, England)
|
September 8, 2005
Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable
E Parellada, R Andrezina, V Milanova, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 1, 1994
Prefrontal and temporal blood flow in schizophrenia: resting and activation technetium-99m-HMPAO SPECT patterns in young neuroleptic-naive patients with acute disease
A M Catafau, E Parellada, F J Lomeña, et al.
Translational Psychiatry
|
August 26, 2015
Apoptotic markers in cultured fibroblasts correlate with brain metabolites and regional brain volume in antipsychotic-naive first-episode schizophrenia and healthy controls
A Batalla, N Bargalló, P Gassó, et al.
Journal of Psychopharmacology (Oxford, England)
|
March 1, 2008
Pharmacokinetics and time-course of D(2) receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients
A M Catafau, M M Penengo, G Nucci, et al.
Psychiatry Research
|
September 1, 2001
Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint
M Bernardo, E Parellada, F Lomeña, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
December 15, 2022
Early treatment with JNJ-46356479, a mGluR2 modulator, improves behavioral and neuropathological deficits in a postnatal ketamine mouse model of schizophrenia
A Martínez-Pinteño, N Rodríguez, D Olivares, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists
|
January 4, 2017
Metabolic syndrome or glucose challenge in first episode of psychosis?
C Garcia-Rizo, E Fernandez-Egea, C Oliveira, et al.
Survey of Ophthalmology
|
January 2, 2026
Assessing the three pillars of housing for eye and vision health outcomes: A scoping review
Sofia E Parellada, Kishan Avaiya, Khawla M Elnour, et al.
Acta Psychiatrica Scandinavica
|
November 21, 2019
Personalized medicine begins with the phenotype: identifying antipsychotic response phenotypes in a first-episode psychosis cohort
S Mas, P Gassó, N Rodríguez, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 31) with videos related to
Sort By:
Page
of 4
Revista Espanola De Medicina Nuclear
|
June 10, 2006
[Striatal dopamine transporter density decrease in first episode schizophrenic patients treated with risperidone]
J J Mateos, F Lomeña, E Parellada, et al.
Journal of Psychopharmacology (Oxford, England)
|
September 8, 2005
Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable
E Parellada, R Andrezina, V Milanova, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 1, 1994
Prefrontal and temporal blood flow in schizophrenia: resting and activation technetium-99m-HMPAO SPECT patterns in young neuroleptic-naive patients with acute disease
A M Catafau, E Parellada, F J Lomeña, et al.
Translational Psychiatry
|
August 26, 2015
Apoptotic markers in cultured fibroblasts correlate with brain metabolites and regional brain volume in antipsychotic-naive first-episode schizophrenia and healthy controls
A Batalla, N Bargalló, P Gassó, et al.
Journal of Psychopharmacology (Oxford, England)
|
March 1, 2008
Pharmacokinetics and time-course of D(2) receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients
A M Catafau, M M Penengo, G Nucci, et al.
Psychiatry Research
|
September 1, 2001
Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint
M Bernardo, E Parellada, F Lomeña, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
December 15, 2022
Early treatment with JNJ-46356479, a mGluR2 modulator, improves behavioral and neuropathological deficits in a postnatal ketamine mouse model of schizophrenia
A Martínez-Pinteño, N Rodríguez, D Olivares, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists
|
January 4, 2017
Metabolic syndrome or glucose challenge in first episode of psychosis?
C Garcia-Rizo, E Fernandez-Egea, C Oliveira, et al.
Survey of Ophthalmology
|
January 2, 2026
Assessing the three pillars of housing for eye and vision health outcomes: A scoping review
Sofia E Parellada, Kishan Avaiya, Khawla M Elnour, et al.
Acta Psychiatrica Scandinavica
|
November 21, 2019
Personalized medicine begins with the phenotype: identifying antipsychotic response phenotypes in a first-episode psychosis cohort
S Mas, P Gassó, N Rodríguez, et al.
Page
of 4